Tyme Technologies (TYME) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. DMART:IN
8. HUM
9. CSCO
10. KTOS

Go back to Tyme Technologies (TYME) Misses Q1 EPS by 3c

TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results

August 10, 2021 6:45 AM EDT

Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings

- Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer, with Georgetown University

- Granted U.S. patent claims covering use of tyrosine-based drug delivery method to treat cancer -

Appointed acting Chief Medical Officer Dr. Jan M. Van Tornout, and Chief Financial Officer, Frank Porfido -

... More